Method of treating diseases arising from platelet hyperactivation
US4728660A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jun 11, 1984 |
| Grant date | Mar 1, 1988 |
| Priority date | — |
| Expiry date | Jun 11, 2004 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/84
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
Calcium (Ca.sup.2+) channel blockers, such as nifedipine and verapamil, are used in the treatment of thromboembolic diseases such as stroke and peripheral vascular occlusive diseases, especially arterial and venous thrombosis, vasculitis, myelofibrosis disease and hemolytic anemias. Such diseases arise from platelet hyperactivation and the Ca.sup.2+ channel blockers restore the platelets to their normal aggregation characteristics. Diagnostic procedures for detecting platelet hyperactivation and defective calcium handling/transport indicative of certain peripheral obstructive diseases using chlorotetracycline as a detectable fluorescent probe as a means of assessing a patient's response to Ca.sup.2+ channel blockers in the therapy of such diseases are also described.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.